FGF23 and chronic kidney disease: Additionally, a clinical trial using ferric citrate, an iron-containing phosphate binder, to treat IDA in CKD patients showed circulating FGF23 levels were reduced,52 highlighting the role of iron provision to suppress FGF23, potentially through direct actions on osteocytes.